Walvax Biotechnology Co., Ltd. (SHE:300142)

China · Delayed Price · Currency is CNY

14.23

+0.74 (5.49%)

Sep 30, 2026, 3:04 PM CST

Market Cap	22.76B +23.4%
Revenue (ttm)	2.10B -17.5%
Net Income	188.77M +1,178.9%
EPS	0.12 +1,163.9%
Shares Out	1.60B
PE Ratio	121.26
Forward PE	n/a
Dividend	0.16 (1.09%)
Ex-Dividend Date	Jun 24, 2026

Volume	153,642,040
Open	13.56
Previous Close	13.49
Day's Range	13.50 - 14.50
52-Week Range	10.88 - 16.97
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis c... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 1,981

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300142

Full Company Profile

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.

Financial Statements